ATAnthony Tang

Anthony Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anthony Tang has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence, burden and manifestation of atrial fibrillation: a large-scale analysis of cardiac patch monitors

    by Sophie Sigfstead, David Newman, Isabelle Nault, David Gladstone, Anthony Tang, Laurent Macle, Jeffrey S Healey, Jason G Andrade, Riyaz A Kaba, Christopher C Cheung

    Background: Atrial fibrillation (AF) is frequently paroxysmal and asymptomatic, making its detection and burden quantification challenging. The distribution of AF burden across clinically monitored populations remains poorly characterised. We sought to describe the distribution of AF burden and its variation by monitoring indication, symptomatology, arrhythmia characteristics and geography. Methods: This study analysed cardiac patch monitor reports collected between May 2017 and July 2023. Analyses were stratified by monitoring indication, AF burden grouping and geography. AF burden subgroups were defined based on the burden detected during recording, and divided into four subgroups: (1) no AF (AF burden=0%); (2) low burden AF (>0 to ≤10%); (3) moderate burden AF (>10% to <100%); and (4) continuous AF (100%). Results: Across 142 346 monitoring reports, AF was detected in 15 678 cases (11.17%), with a median AF burden of 100% (IQR 4.67–100.00). When stratified by monitoring indication, AF was detected in 28.2% of monitors indicated due to suspected or history of AF, 4.5% for stroke/transient ischaemic attack (TIA), 6.5% for syncope/pre-syncope and 4.9% for palpitations. In the stroke/TIA monitoring population, AF detection was time-dependent, with 58.8% of cases identified within 24 hours, increasing to 88.0% identified at 7 days. Among all patients with AF detected, patients with continuous AF (100% AF burden) exhibited lower heart rates and symptom burden compared with those with low (≤10%) and moderate (10% to <100%) AF burden. AF detection was higher in the UK than Canada (12.2% vs 10.9%), as was median burden among detected cases (100.0 vs 55.0%), despite shorter prescribed monitoring durations in the UK (median 48.00 hours (IQR 24.00–168.00) vs 168.00 hours (IQR 168.00–336.00)). Conclusions: In patients undergoing clinically indicated patch monitoring, AF burden varied by monitoring indication, symptomatology and geography, identifying potentially distinct AF subgroups. Characterising AF burden can inform the development and evaluation of AF monitoring and treatment strategies.


  • Open Access

    Prediction of Pulmonary Vein Isolation and Gap Recurrence on 12-Lead ECG Using Deep Learning

    by Iris Liu, Meichen Liu, Isabelle Ah-Sen, Wenteng Hou, Habib Rehman Khan, Christopher C. Cheung, Lorne J. Gula, Anthony S.L. Tang, Jaimie Manlucu, Peter Leong-Sit, et al.

    Background: Pulmonary vein isolation (PVI) is key to atrial fibrillation (AF) ablation, but arrhythmia often recurs due to conduction gaps permitting pulmonary vein (PV) reconnection. Currently, gap identification requires invasive remapping. We evaluated whether deep learning applied to surface electrocardiograms (ECGs) could (i) detect the electrophysiologic signature of PVI and (ii) predict PV reconnection at redo ablation. Methods: We retrospectively studied 176 patients (2012–2023) who had initial PVI and repeat ablation. A total of 865 10-second 12-lead ECGs were extracted from GE MUSE and CardioLab systems, segmented into 1-2 second clips, and used to train ResNet-based convolutional neural networks. Separate models were developed for: (i) PVI detection (pre-vs. post-ablation ECGs) and (ii) gap prediction using pre-redo ECGs. Demographic features were tested alone and in multimodal fusion with ECGs. Performance was evaluated using Receiver Operating Characteristic (ROC) curves, sensitivity, and specificity with stratified cross-validation. Gradient-weighted class activation mapping (Grad-CAM) assessed feature importance. Results: The best PVI detection model distinguished ECGs before and after PVI with the area under the ROC (AUROC) = 0.879. Grad-CAM localized attention to the diastolic period and P-wave morphology. For gap prediction, the model trained on pre-redo ECGs achieved an AUROC of 0.819 (sensitivity 77.5%, specificity 75.8%). Adding demographics improved the AUROC to 0.830 (sensitivity 84%, specificity 72%), whereas demographics alone performed no better than chance (AUROC = <50%). Feature importance analysis highlighted P-wave onset and offset, inter-ablation time interval, left atrial volume index, age, and left ventricular ejection function as the strongest contributors in gap prediction. Conclusions: Deep learning identifies a consistent ECG biosignature of acute PVI and predicts PV reconnection before redo ablation with moderate accuracy, primarily using P-wave morphology. These models may inform patient selection, procedural planning, and counselling in patients with recurrent AF after PVI. GRAPHICAL CLINICAL PERSPECTIVE: What is Known: Arrhythmia recurrence post-pulmonary vein isolation (PVI) are commonly caused by conduction gaps in the PV, and repeat isolation procedures lead to better arrhythmia-free survival compared to if recurrences are due to extrapulmonary triggers with chronically isolated veins. Currently, there are no non-invasive methods to detect conduction gaps after PVI. What the Study Adds: Our deep learning models can predict the presence of conduction gaps from non-invasive surface electrocardiograms prior to repeat procedures with moderate accuracy. We identified important ECG and demographic features in predicting gap presence. Ultimately, we provide potential methods of risk-stratifying patients and selecting candidates for repeat procedures that can be accessed in outpatient settings.

  • Open Access

    Outcomes of Cardiac Resynchronization Therapy by New York Heart Association Class: A Patient‐Level Meta‐Analysis

    by Nishkala Shivakumar, Daniel J. Friedman, Marat Fudim, William T. Abraham, John G. F. Cleland, Anne B. Curtis, Michael R. Gold, Valentina Kutyifa, Cecilia Linde, James Young, et al.

    Background: Data on the benefits of cardiac resynchronization therapy (CRT) in patients with severe heart failure symptoms are limited. We investigated the relative effects of CRT in patients with ambulatory New York Heart Association (NYHA) IV versus III functional class at the time of device implantation. Methods and Results: In this meta‐analysis, we pooled patient‐level data from the MIRACLE (Multicenter InSync Randomized Clinical Evaluation), MIRACLE‐ICD (Multicenter InSync Implantable Cardioversion Defibrillation Randomized Clinical Evaluation), and COMPANION (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure) trials. Outcomes evaluated were time to the composite end point of the first heart failure hospitalization or all‐cause mortality, and time to all‐cause mortality alone. The association between CRT and outcomes was evaluated using a Bayesian hierarchical Weibull survival regression model. We assessed if this association differed between NYHA III and IV groups by adding an interaction term between CRT and NYHA class as a random effect. A sensitivity analysis was performed by including data from RAFT (Resynchronization‐Defibrillation for Ambulatory Heart Failure). Our pooled analysis included 2309 patients. Overall, CRT was associated with a longer time to heart failure hospitalization or all‐cause mortality (adjusted hazard ratio [aHR], 0.79 [95% credible interval [CI], 0.64–0.99]; posterior probability or P =0.044), with a similar association with time to all‐cause mortality (aHR, 0.78 [95% CI, 0.59–1.03]; P =0.083). Associations of CRT with outcomes were not significantly different for those in NYHA III and IV classes (ratio of aHR, 0.72 [95% CI, 0.30–1.27]; P =0.23 for heart failure hospitalization/mortality; ratio of aHR, 0.70 [95% CI, 0.35–1.34]; P =0.27 for all‐cause mortality alone). The sensitivity analysis, including RAFT data, did not show a significant relative CRT benefit between NYHA III and IV classes. Conclusions: Overall, there was no significant difference in the association of CRT with either outcome for patients in NYHA functional class III compared with functional class IV.


  • Open Access

    Outcomes of Cardiac Resynchronization Therapy by New York Heart Association Class: A Patient-Level Meta-Analysis

    by Nishkala Shivakumar, Daniel J. Friedman, Marat Fudim, William T. Abraham, John G. F. Cleland, Anne B. Curtis, Michael R. Gold, Valentina Kutyifa, Cecilia Linde, James Young, et al.

    Data on the benefits of cardiac resynchronization therapy (CRT) in patients with severe heart failure (HF) symptoms are limited. We investigated the relative effects of CRT in patients with ambulatory NYHA IV vs. III functional class at the time of device implantation. In this meta-analysis, we pooled patient-level data from the MIRACLE, MIRACLE-ICD, and COMPANION trials. Outcomes evaluated were time to the composite endpoint of first HF hospitalization (HFH) or all-cause mortality and time to all-cause mortality alone. The association between CRT and outcomes was evaluated using a Bayesian Hierarchical Weibull survival regression model. We assessed if this association differs between NYHA III and IV groups by adding an interaction term between CRT and NYHA class as a random effect. A sensitivity analysis was performed by including data from the RAFT trial. Our pooled analysis included 2309 patients. Overall, CRT was associated with a longer time to HFH or all-cause mortality (adjusted hazard ratio [aHR] 0.79, 95%CI 0.64 – 0.99, p = 0.044), with a similar association with time to all-cause mortality (aHR 0.78, 95% CI 0.59 – 1.03, p = 0.083). Associations of CRT with outcomes were not significantly different for those in NYHA III and IV classes (ratio of aHR 0.72, 95% CI 0.30 – 1.27, p = 0.23 for HFH/mortality; ratio of aHR 0.70, 95% CI 0.35 – 1.34, p = 0.27 for all-cause mortality alone). The sensitivity analysis, including RAFT data, did not show a significant relative CRT benefit between NYHA III and IV classes. Overall, there was no significant difference in the association of CRT with either outcome for patients in NYHA functional class III compared with functional class IV.


  • Open Access

    Health Security Perceptions: Initial Psychometric Analysis of the Construct of Health Security in Chronic Illness Among Patients With a Cardiac Device

    by Zachary M. Force, Ratika Parkash, Anthony Tang, Shannon E. Kelly, George Wells, Evan Lockwood, Amir AdelWahab, Isabelle Nault, Jeff Healey, Karen A. Giddens, et al.


  • Open Access

    Approach to a patient with asymptomatic pre-excitation

    by Pavel Antiperovitch, Allan Skanes, George Klein, Anthony Tang


  • Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials

    by Daniel J. Friedman, Sana M. Al-Khatib, Frederik Dalgaard, Marat Fudim, William T. Abraham, John G.F. Cleland, Anne B. Curtis, Michael R. Gold, Valentina Kutyifa, Cecilia Linde, et al.

    Background: Benefit from cardiac resynchronization therapy (CRT) varies by QRS characteristics; individual randomized trials are underpowered to assess benefit for relatively small subgroups. Methods: The authors analyzed patient-level data from pivotal CRT trials (MIRACLE [Multicenter InSync Randomized Clinical Evaluation], MIRACLE-ICD [Multicenter InSync ICD Randomized Clinical Evaluation], MIRACLE-ICD II [Multicenter InSync ICD Randomized Clinical Evaluation II], REVERSE [Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction], RAFT [Resynchronization-Defibrillation for Ambulatory Heart Failure], BLOCK-HF [Biventricular Versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block], COMPANION [Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure], and MADIT-CRT [Multicenter Automatic Defibrillator Implantation Trial – Cardiac Resynchronization Therapy]) using Bayesian Hierarchical Weibull survival regression models to assess CRT benefit by QRS morphology (left bundle branch block [LBBB], n=4549; right bundle branch block [RBBB], n=691; and intraventricular conduction delay [IVCD], n=1024) and duration (with 150-ms partition). The continuous relationship between QRS duration and CRT benefit was also examined within subgroups defined by QRS morphology. The primary end point was time to heart failure hospitalization (HFH) or death; a secondary end point was time to all-cause death. Results: Of 6264 patients included, 25% were women, the median age was 66 [interquartile range, 58 to 73] years, and 61% received CRT (with or without an implantable cardioverter defibrillator). CRT was associated with an overall lower risk of HFH or death (hazard ratio [HR], 0.73 [credible interval (CrI), 0.65 to 0.84]), and in subgroups of patients with QRS ≥150 ms and either LBBB (HR, 0.56 [CrI, 0.48 to 0.66]) or IVCD (HR, 0.59 [CrI, 0.39 to 0.89]), but not RBBB (HR 0.97 [CrI, 0.68 to 1.34]; P interaction <0.001). No significant association for CRT with HFH or death was observed when QRS was <150 ms (regardless of QRS morphology) or in the presence of RBBB. Similar relationships were observed for all-cause death. Conclusions: CRT is associated with reduced HFH or death in patients with QRS ≥150 ms and LBBB or IVCD, but not for those with RBBB. Aggregating RBBB and IVCD into a single “non-LBBB” category when selecting patients for CRT should be reconsidered. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT00271154, NCT00251251, NCT00267098, and NCT00180271.


  • Open Access

    Influence of the Social Environment on Ideal Cardiovascular Health

    by Sarah S. Singh, Saverio Stranges, Piotr Wilk, Anthony S. L. Tang, Stephanie J. Frisbee

    Background: The environment plays a large role in the health of individuals; however, more research is needed to better understand aspects of the environment that most influence health. Specifically, our study examines how the social environment influences cardiovascular health (CVH). Methods and Results: The social environment was characterized using measures of belonging and life and work stress in individuals, as well as nationally derived measures of marginalization, deprivation, economic status, and community well‐being in neighborhoods. CVH was defined by the American Heart Association's Cardiovascular Health Index—a summed score of 7 clinical and behavioral components known to have the greatest impact on CVH. Data were obtained from the Canadian Community Health Survey 2015 to 2016 and multiple national data sources. Multilevel regression models were used to analyze the associations between CVH and the social environment. Overall, 27% of Canadians reported ideal CVH (6–7 score points), 68% reported intermediate CVH (3–5 score points), and 5% reported poor CVH (0–2 score points). The neighborhood environment contributed up to 7% of the differences in CVH between individuals. Findings indicated that residing in a neighborhood with greater community well‐being (odds ratio [OR], 1.33 [95% CI, 1.26–1.41]) was associated with achieving higher odds of ideal CVH, while weaker community belonging (OR, 0.67 [95% CI, 0.62–0.72]) and residing in a neighborhood with greater marginalization (OR, 0.87 [95% CI, 0.82–0.91]) and deprivation (OR, 0.67 [95% CI, 0.64–0.69]) were associated with achieving lower odds of ideal CVH. Conclusions: Aspects of individual‐level social environment and residing in a neighborhood with a more favorable social environment were both independently and significantly associated with achieving ideal CVH.


  • Is Maintenance of Sinus Rhythm of Value in Patients with Atrial Fibrillation and Heart Failure?

    by Mouhannad M. Sadek, Allan Skanes, Anthony S. L. Tang

    Purpose of Review Heart failure (HF) and atrial fibrillation (AF) frequently co-exist, with the prevalence of AF increasing in patients with more advanced HF symptoms. When present, AF increases morbidity and mortality in patients with HF. The purpose of this review is to examine emerging evidence addressing the value of restoration and maintenance of sinus rhythm in patients with HF. Recent Findings Earlier trials comparing a rhythm control strategy with antiarrhythmic drugs have failed to demonstrate benefit in patients with HF and reduced ejection fraction. More recent trials, including the recently published RAFT-AF, utilizing catheter ablation for rhythm control, have shown greater promise, possibly due to reduced medication-related side effects and higher efficacy in maintaining sinus rhythm. Summary A strategy of sinus rhythm maintenance with catheter ablation appears to improve mortality, reduce HF events and improve quality of life in patients with AF and HF.